ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Nathan T. Connell; Veronica H. Flood; Romina Brignardello‐Petersen; Rezan A. Kadir; Alice Arapshian; Susie Couper; Jean M. Grow; Peter A. Kouides; Michael Laffan; Michelle Lavin; Frank W.G. Leebeek; Sarah H. O’Brien; Margareth C. Ozelo; Alberto Tosetto; Angela C. Weyand; Paula James; Mohamad A. Kalot; Nedaa Husainat; Reem A. Mustafa

doi:10.1182/bloodadvances.2020003264

Key Points

To provide evidence-based clinical practice recommendations for the prevention, evaluation, and management of bleeding in individuals with von Willebrand disease.
Collaborative development of clinical recommendations by ASH, ISTH, NHF, and WFH expert panels based on comprehensive evidence reviews.
Evaluated interventions across multiple domains including surgical hemostasis, desmopressin trials, obstetrics, and antithrombotic therapy.
Provides recommendations for long-term bleeding prophylaxis in recurrent hemorrhage and trial protocols for desmopressin response testing.
Establishes target von Willebrand factor and factor VIII activity thresholds for major surgical procedures and interventions for minor procedures.
Outlines management strategies for heavy menstrual bleeding, neuraxial anesthesia during labor and delivery, postpartum care, and antithrombotic drug use.

Structured PICO

P

Population

Patients with von Willebrand disease

I

Intervention

Management strategies including prophylaxis, desmopressin trials, antiplatelet/anticoagulant therapy, and periprocedural care

Provides the 2021 ASH/ISTH/NHF/WFH clinical practice guidelines for the management of von Willebrand disease.

Implication

Guides VWD management in surgery, delivery, and bleeding; leaves open need for prospective validation of recommendations.

Abstract

These guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Connell et al. (2021) studied this question.

synapsesocial.com/papers/69d570e375589c71d767dfc9 https://doi.org/10.1182/bloodadvances.2020003264

View Full Paper

Ask AI

Bookmark

Share

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading